Actively Recruiting
Phase 12 Study to Evaluate Safety and Explore Effectiveness of TC011 CAR-T Therapy in Adults with Relapsed or Refractory Large B-Cell Non-Hodgkin Lymphoma
Led by TICAROS Co., Ltd. · Updated on 2026-03-16
98
Participants Needed
1
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and potential effects of TC011, an anti-CD19 Chimeric Antigen Receptor T cell CAR-T therapy, in adults with relapsed or refractory large B-cell non-Hodgkin lymphoma. This multi-center, phase III open-label study focuses on patients who have had at least two prior lines of systemic chemotherapy and have measurable lymphoma lesions. The study is sponsored by TICAROS Co., Ltd. and aims to explore both safety and efficacy outcomes. Participants will first receive a conditioning chemotherapy regimen consisting of fludarabine and cyclophosphamide, followed by the investigational treatment TC011. The study includes two phases Phase 1 focuses on determining dose-limiting toxicities, maximum tolerated dose, and recommended Phase 2 dose, while Phase 2 primarily assesses objective response rates and disease control over time. Treatment monitoring includes physical exams, vital signs, ECG, laboratory tests, and detection of replication-competent lentivirus. During the study, participants will be closely monitored for adverse events and treatment responses at multiple timepoints up to 96 weeks after TC011 infusion. Assessments will include response rates, progression-free survival, overall survival, and time to response. Safety evaluations continue through week 12. The total duration of participation varies depending on phase and follow-up schedules, with frequent visits for clinical and laboratory evaluations to track treatment impact and safety.
CONDITIONS
Brief Title
Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients
Research Team
A
Ah hyun Lim
A
admin
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here